In conclusion, our novel data indicate that TRPV4-signaling can be recruited as a novel target to combat diabetic retinopathy, which is characterized by permeability changes that can be attenuated by endogenous vasoinhibins, which combine synergistically with selective TRPV4 blockers. Here, TRPV4 is linked to diabetic retinopathy.